However, the drug does not reduce the size of the reservoir.
July 31, 2017
____________________________________________________________________________________
____________________________________________________________________________________
Given in 72-hour intervals, the drug varinostat helps reveal HIV that
is harbored in unreplicating cells, but on its own, at least, it does
not apparently deplete the volume of such reservoir cells.
Made
up of unreplicating, or latent, cells infected with HIV, the viral
reservoir frustrates attempts to cure the virus because these cells
remain under the radar of standard antiretroviral (ARV) treatment, which
works only when cells are replicating.
Publishing
their findings in the Journal of Clinical Investigation, researchers
studied the HDAC inhibitor vorinostat in 16 people on fully suppressive
ARV treatment for HIV. The participants received doses of the drug every
48 or 72 hours as the investigators sought to determine the optimal
dosing interval.
The study authors found that
vorinostat more effectively revealed unreplicating HIV-infected cells
when dosed every 72 hours. Despite the fact that vorinostat is used to
spur the replication of latently infected cells, its use in these
participants did not cause a rise in viral load.
After
more than a month of vorinostat treatment, participants experienced few
side effects and no serious toxicities. However, the size of the viral
reservoir apparently did not taper.
The researchers are
now conducting two small studies in which they are pairing vorinostat
with one of two other agents—an anti-HIV vaccine or an infusion of
antiviral immune cells—in hopes that the combined effects will help
shrink the viral reservoir. The investigators are not expecting
immediate success but hope to build on the knowledge they gain from such
research, with the ultimate goal of eventually clearing HIV from the
body.
To read a press release about the study, click here.
To read the study, click here.
Read more articles from POZ, here.